iifl-logo-icon 1

Aarti Drugs Ltd Share Price

523.95
(-1.65%)
Jul 18, 2024|03:32:00 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open530
  • Day's High538.45
  • 52 Wk High645.75
  • Prev. Close532.75
  • Day's Low519.05
  • 52 Wk Low431.05
  • Turnover (lac)1,113.78
  • P/E34.54
  • Face Value10
  • Book Value136.57
  • EPS15.43
  • Mkt. Cap (Cr.)4,816.93
  • Div. Yield0.19
No Records Found

Aarti Drugs Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

530

Prev. Close

532.75

Turnover(Lac.)

1,113.78

Day's High

538.45

Day's Low

519.05

52 Week's High

645.75

52 Week's Low

431.05

Book Value

136.57

Face Value

10

Mkt Cap (₹ Cr.)

4,816.93

P/E

34.54

EPS

15.43

Divi. Yield

0.19

Aarti Drugs Ltd Corporate Action

4 Sep 2023

12:00 AM

AGM

Announcement Date: 04 Sep, 2023

arrow

24 Jan 2024

12:00 AM

Dividend

Dividend Amount: 1

Record Date: 06 Feb, 2024

arrow

26 Apr 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Aarti Drugs Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Aarti Drugs Ltd SHAREHOLDING SNAPSHOT

18 Jul, 2024|07:38 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 57.13%

Foreign: 0.00%

Indian: 57.13%

Non-Promoter- 8.55%

Institutions: 8.55%

Non-Institutions: 34.31%

Custodian: 0.00%

Share Price

Aarti Drugs Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

92.6

92.6

93.2

23.3

Preference Capital

0

0

0

0

Reserves

1,021.7

879.57

766.41

598.49

Net Worth

1,114.3

972.17

859.61

621.79

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

2,251.17

1,914.89

1,634.92

1,140.45

yoy growth (%)

17.56

17.12

43.35

4.75

Raw materials

-1,480.52

-1,139.91

-1,045.87

-700.52

As % of sales

65.76

59.52

63.97

61.42

Employee costs

-69.31

-69.28

-60.09

-50.48

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

255.49

337.48

166.59

112.21

Depreciation

-47.39

-47.59

-46.66

-37.79

Tax paid

-60.5

-80

-39.3

-38.8

Working capital

194.84

155.99

28.06

98.02

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

17.56

17.12

43.35

4.75

Op profit growth

-20.7

64.17

34.4

3.66

EBIT growth

-23.47

81.13

36.89

2.07

Net profit growth

-24.33

89.94

84.81

-2.73

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

2,528.58

2,716.05

2,488.65

2,154.78

1,806.09

Excise Duty

0

0

0

0

0

Net Sales

2,528.58

2,716.05

2,488.65

2,154.78

1,806.09

Other Operating Income

0

0

0

0

0

Other Income

4.03

2.19

11.32

4.74

5.95

Aarti Drugs Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,579.3

124.153,78,914.98867.60.855,536.9998.75

Cipla Ltd

CIPLA

1,510.4

32.861,22,044.231,038.40.563,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,570.8

76.931,21,185.085310.662,259507.93

Zydus Lifesciences Ltd

ZYDUSLIFE

1,184.8

34.691,19,223.631,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,646.05

25.871,10,827.471,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Aarti Drugs Ltd

Management

Register Office

Registrar Office

CMD & Executive Director

Prakash M Patil

ED / MD / Promoter

Rashesh C Gogri

ED / Joint MD / Promoter

Harshit M Savla

E D & Wholetime Director

Harit P Shah

WTD & Executive Director

Uday M Patil

Non Executive Director

Narendra Jagannath Salvi

Independent Non Exe. Director

Navin Chapshi Shah

Independent Non Exe. Director

Krishnacharya G Akamanchi

Independent Non Exe. Director

Priti Savla

Independent Non Exe. Director

Ankit Vikram Paleja

Independent Non Exe. Director

Bhaskar Narayan Thorat

Independent Non Exe. Director

Neha Gada

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra. It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries, Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries.The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs), Steroids, Pharmaceutical Intermediates, and Specialty Chemicals, such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in September 28th, 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for im
Read More

Company FAQs

What is the Aarti Drugs Ltd share price today?

Down Arrow

The Aarti Drugs Ltd shares price on N/A is Rs.₹524.25 today.

What is the Market Cap of Aarti Drugs Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aarti Drugs Ltd is ₹4819.69 Cr. as of 18 Jul ‘24

What is the PE and PB ratio of Aarti Drugs Ltd?

Down Arrow

The PE and PB ratios of Aarti Drugs Ltd is 34.54 and 4.17 as of 18 Jul ‘24

What is the 52 Week High and Low of Aarti Drugs Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Aarti Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Aarti Drugs Ltd is ₹430 and ₹645 as of 18 Jul ‘24

What is the CAGR of Aarti Drugs Ltd?

Down Arrow

Aarti Drugs Ltd's CAGR for 5 Years at 33.13%, 3 Years at -9.96%, 1 Year at 5.39%, 6 Month at 0.05%, 3 Month at 7.72% and 1 Month at 2.16%.

What is the shareholding pattern of Aarti Drugs Ltd?

Down Arrow

The shareholding pattern of Aarti Drugs Ltd is as follows:
Promoters - 57.13 %
Institutions - 8.55 %
Public - 34.31 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.